Original reporting and analysis on the stories shaping biotech.
BioNTech's co-founders are leaving the $20 billion company they built to start a brand-new mRNA venture. The stock cratered 20%, no successor has been named, and Wall Street is scrambling to figure out what comes next.
A tiny San Diego biotech spent six years building a molecular glue platform, only to shut down in a field where Big Pharma is pouring billions. The science was hot; the funding wasn't.
AbbVie and Regeneron dropped obesity drug data on the same day, and neither is trying to be the next Ozempic. One showed nearly 10% weight loss in just 12 weeks through a completely different mechanism; the other posted 19% weight loss with dramatically fewer side effects than Zepbound.
ARPA-H just launched the Delphi program to build tiny, Lego-like biosensor "chiplets" that track hormones, inflammation, and medication levels in real time. It could be the biggest leap from Fitbit-grade wellness tracking to actual clinical diagnostics, and researchers have until April 8 to pitch.
The world's biggest drugmakers cut their antibiotic pipelines by 35% in five years, even as superbugs grow deadlier. A new report reveals a dangerous retreat from the drugs modern medicine can't function without.
Takeda's oral psoriasis drug zasocitinib just crushed its Phase 3 trials with biologic-level skin clearance rates. With peak sales estimates of up to $6 billion, the $4 billion acquisition that spawned it might be biotech's best bargain.
BMS's experimental drug mezigdomide just cleared its first phase 3 hurdle in multiple myeloma, validating an entirely new class of cancer drugs called CELMoDs. But the real showdown against the company's own blockbuster predecessor is still a year away.
GSK sold its severe itch drug linerixibat to Alfasigma for $300 million, just two weeks before an FDA decision. The deal reveals how Big Pharma is shedding promising niche assets to chase bigger markets.
Xenon Pharmaceuticals' epilepsy drug azetukalner just posted Phase 3 results that sent the stock soaring 48% in a single day. With the highest placebo-adjusted efficacy ever reported in a pivotal epilepsy trial and a completely novel mechanism of action, Wall Street analysts are already calling it a potential "medicine of choice."
Vertex Pharmaceuticals dropped $4.9 billion on a kidney drug most people had never heard of. The phase 3 results just came in, and Wall Street is scrambling to update its models.
The FDA just approved the first once-weekly treatment for achondroplasia, turning seven daily shots into one. But Ascendis Pharma is walking into a three-way competitive fight that could reshape the dwarfism treatment landscape.
Candid Therapeutics just went public without an IPO, pulling off a $505 million reverse merger with Rallybio that left Candid shareholders owning 96.3% of the company. It's one of the biggest backdoor listings biotech has ever seen, and investors were fighting to get in.
Alfasigma just paid $300 million upfront for GSK's late-stage itch drug, with an FDA decision landing in just two weeks. The deal could reach $690 million if everything goes right, but the clock is ticking on the biggest "if" in specialty pharma.
Roche's oral SERD giredestrant just failed its biggest phase 3 test in first-line breast cancer, sending shares tumbling and casting doubt over the entire drug class. But the full story is stranger than the headline suggests.
The FTC is reviewing Gilead's $7.8 billion acquisition of Arcellx, catching the biotech industry off guard during its biggest M&A boom in years. The scrutiny could reshape how every pharma company approaches dealmaking in 2026.
Bavarian Nordic's CEO is stepping down after the board backed a $3.1 billion PE takeover that shareholders rejected. With the mpox boom fading and the stock trading below fair value, the Danish vaccine maker is suddenly one of biotech's most interesting chess pieces.
GSK just wrote a $950 million check for a drug that's never been tested in a patient. The target: a potentially massive pulmonary hypertension market projected to hit $18 billion. The gamble hinges on whether one molecule can outperform Merck's blockbuster Winrevair.
Servier is dropping $2.5 billion in cash on Day One Biopharmaceuticals, a one-drug biotech focused on pediatric brain tumors. The deal says something fascinating about where precision oncology is heading, and why rare cancers might be pharma's smartest bet.
Vertex Pharmaceuticals just laid off 20 people while posting $12 billion in revenue and nearly $4 billion in profit. The tiny cut at biotech's most successful company tells a much bigger story about how even winners are reshuffling for what comes next.
Alltrna, Flagship Pioneering's $159 million bet on engineered tRNA medicines, just lost its CEO and cut 35% of its workforce in one fell swoop. It's the company's third round of layoffs, and it's part of a bigger pattern hitting Flagship's portfolio.
IQVIA is paying $145 million for Charles River's European discovery labs and AI platform, giving it something it's never had: real drug discovery muscle from day one. The deal bets big on non-animal testing methods and AI-driven chemistry at a moment when regulators are rewriting the rules of preclinical research.
The FDA's most controversial gatekeeper is leaving for the second time in a year. Vinay Prasad's chaotic tenure atop CBER, the center overseeing gene therapies, vaccines, and biologics, leaves behind workplace investigations, rare disease fury, and a regulatory landscape nobody can predict.
Join thousands of biotech professionals who start their day with our free, daily briefing.